Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: January 11th 2023 | Updated: October 8th 2024
IO/IO Versus IO/TKI Frontline Therapy for Intermediate-Risk RCC
Published: August 20th 2024 | Updated: October 8th 2024
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
Published: March 8th 2024 | Updated: October 8th 2024
Selection of First-Line NSCLC Therapy Influenced by Delayed Testing
Published: January 6th 2023 | Updated: October 8th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: October 1st 2024 | Updated: October 8th 2024
Clinical Considerations with Axtilimab in R/R GVHD